Cristiane Bergerot, Former Postdoc Fellow and Research Consultant at City of Hope, shared several articles on X:
1.“Long-term follow-up revealed a clinically meaningful exploratory overall survival benefit despite a negative primary PFS analysis, underscoring the value of mature survival data in immunotherapy trials.”
Title: Final Results From the ATALANTE/ENGOT-ov29 Randomized Phase III Trial of Atezolizumab, Bevacizumab, and Platinum-Based Therapy for Late-Relapsing Recurrent Ovarian Cancer
Authors: Jean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, Lisa Belin, Christoph Grimm, Roman Kocián, Hannelore Denys, Ora S. Rosengarten, Philippe Follana, Jalid Sehouli, Jeronimo Martinez García, Jérôme Alexandre, Anne-Claire Hardy-Bessard, Jean-Sébastian Frenel, Renaud Sabatier, Laurence Gladieff, Thibault De La Motte Rouge, Nathalie Bonichon Lamichhane, Elsa Kalbacher, Florian Heitz
2.“Pembrolizumab-based multimodal therapy was feasible, with manageable toxicity and careful monitoring required for rare serious immune-related events.”
Title: Interim Safety Analysis of a Randomized Phase II Trial Comparing Pembrolizumab With Radiation Versus Pembrolizumab, Olaparib, and Radiation in Localized High-Risk Prostate Cancer
Authors: Zin W. Myint, Donglin Yan, William St. Clair, Stephen Strup, Patrick J. Hensley, Derek B. Allison, Frances M. Martin, Ritesh Kumar, Insija I. Selene, Ashlyn Whitesell, Odei Bismarck, Benjamin L. Maughan
3.“CAST-AI will determine whether biomarker-guided consolidative surgery can improve outcomes after first-line EV/pembrolizumab in advanced urothelial carcinoma.”
Title: CAST-AI: Cystectomy After Systemic Therapy With Antibody-Drug Conjugate and Immunotherapy
Authors: Jabra Zarka, Daniel S. Roberson, Peter F. Rosen, Susanna Gregory, Joanina Gicobi, Lynn M. Flickinger, Olivia Bobek, Joshua C. Pritchett, Anthony Tabiim, Albert Jang, Abhinav Khanna, Elisabeth Heath, Lance Pagliaro, Daniel S. Childs, Brian A. Costello, Karla V. Ballman, Vidit Sharma, John C. Cheville, R. Jeffrey Karnes, Josep Domingo-Domenech, Stephen A. Boorjian, Aadel A. Chaudhuri, Fabrice Lucien, Paras Shah, Jacob J. Orme
Read the Article.
4.“Quality-of-life outcomes remain substantially underreported in GU cancer trials, with evidence suggesting outcome-dependent reporting bias.”
Title: Planning, Reporting, and Selective Disclosure of Quality-of-Life End Points in Phase III Genitourinary Cancer Trials
Authors: Shreyas Kalantri, Shiva Balasubramanian, Jincong Q. Freeman, Tyler Jones, Priyanka Sheth, Srinidhi Karthik, Jason Chesney, Rohit Kumar
5.“A Bayesian multistate approach may enable earlier and more accurate interim decisions in oncology clinical trials.”
Title: Bayesian Multistate Transition Modeling of Response, Progression, and Death to Elucidate Mechanisms of Survival Benefit in Oncology Trials
Authors: Brian P. Hobbs, Qing Liu, Jackie Zhang, Junyi Zhou, Yan Chu, Michael Kane, May Mo, Hong Amy Xia
Other articles featuring Cristiane Bergerot on OncoDaily.